
|Articles|February 6, 2004
Botulinum toxin product study results released
Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
5











